These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
    Author: Wu GQ.
    Journal: Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):47-51. PubMed ID: 7687533.
    Abstract:
    Four patients with advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma (NHL) were treated with high dose chemoradiotherapy and ABMT as a first line therapy. Case 1 was of stage IIIb; case 2, 3 and 4 were of stage IV. Bone marrow was involved (19% blast cells) in case 2, and nervous system was involved in case 4. All of them were given at first an inductive chemotherapy with 3-4 courses of BACOP regimen before ABMT. 40-50 days later, Vp-16, CTX and TBI were given as a conditioning regimen (case 1: TLI). Case 1 and 2 only reached partial remission after inductive treatment (case 2: relapse at primary sites one month after inductive therapy, but complete remission (CR) of bone marrow). All of the four patients reached CR after ABMT. Case 2 had systemic relapse (bone marrow blast cells: 8%) at 110 days after CR and died from relapse 210 days after ABMT. So far, case 1, 3 and 4 have survived free of disease for 24, 19 and 9 months, respectively. There was no fatal marrow transplant regimen-related toxicity during inductive and ABMT treatment. The results of this pilot study suggest that treatment of high-grade malignant NHL may be improved by combined use of high dose chemoradiotherapy and ABMT, and the toxicities can be tolerated.
    [Abstract] [Full Text] [Related] [New Search]